Bone Biologics Corp Dossier - Source-backed chat

Bone Biologics Corp

BBLGNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.71

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.47Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $1.3M

Enterprise Value −$3.2M

Shares Outstanding 2.8M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Bone Biologics Corp (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on bone regeneration in spinal fusion using its proprietary recombinant human protein, NELL-1. The company's lead product candidate, NB1, combines rhNELL-1 with a demineralized bone matrix (DBM) to provide controlled bone regeneration. While the company has achieved significant operational milestones—such as extending the validated shelf life of rhNELL-1 to 29 months and initiating a pilot clinical trial in Australia—it remains a pre-revenue micro-cap entity with typical development-stage risks. BBLG continues to experience ongoing cash burn and relies heavily on equity financing (such as its ATM facility) to fund operations. Given the high-risk, high-reward nature of its clinical pipeline and the lack of near-term commercial revenues, a 'Hold' recommendation is appropriate for investors monitoring clinical trial progression and cash runway.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$12.20

Mean target$12.20

High · most bullish analyst$12.20

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5030%

The bear case involves clinical trial delays, safety concerns, or poor bone fusion efficacy in the Australian pilot study, which would severely damage the viability of the NELL-1 platform. Furthermore, if the company's cash burn accelerates and it fails to raise additional capital on favorable terms, it faces severe dilution or going-concern risks. A drop in stock price below $1.00 could also trigger Nasdaq non-compliance and potential delisting, forcing a highly dilutive reverse stock split.

Base CaseCentral scenario

$3.5050%

The base case assumes steady progression of the Australian pilot clinical trial with patient enrollment completing in late 2026 or early 2027. The company maintains tight expense discipline, keeping its quarterly cash burn manageable, and successfully utilizes its ATM facility to extend its cash runway into 2027 without severe dilution. The stock remains highly volatile but maintains its Nasdaq listing compliance as clinical milestones are gradually achieved.

Bull CaseUpside scenario

$22.2020%

The bull case is driven by successful and rapid enrollment in the Australian pilot clinical trial of NB1, yielding strong safety and efficacy data. Positive clinical readouts would significantly de-risk the NELL-1 platform, paving the way for a pivotal Phase 3 study and potential FDA Pre-Market Approval (PMA) as a Class III medical device. Additionally, further extensions of rhNELL-1's shelf life beyond 29 months would optimize commercial manufacturing scale-up and distribution logistics, attracting strategic partnerships or acquisition interest from larger orthopedic medical device players.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary NELL-1 recombinant human protein platform with exclusive worldwide licensing from UCLA TDG.
Lead product candidate NB1 targets the multi-billion-dollar spinal fusion and bone regeneration market with a highly differentiated osteopromotive mechanism.
Validated shelf life of rhNELL-1 extended to 29 months, significantly improving manufacturing and supply chain flexibility ahead of pivotal trials.
Disciplined cost management has narrowed quarterly net losses, preserving cash reserves.

Key Investment Risks

Pre-revenue developmental stage with no commercial sales and history of operating losses.
High dependence on clinical trial outcomes in Australia, which are subject to enrollment delays and regulatory hurdles.
Limited cash runway, requiring ongoing dilutive equity financing or debt issuance to fund operations.
Risk of Nasdaq minimum bid price non-compliance and potential delisting if the stock price falls below $1.00.

Thesis Invalidation Triggers

Failure of the NB1 pilot clinical trial to meet safety or bone fusion efficacy endpoints.
Inability to secure additional financing, leading to a severe liquidity crisis or going-concern halt.
Delisting from the Nasdaq Capital Market due to failure to maintain the minimum bid price requirement.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.